Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Total Non-Current Liabilities (2016 - 2025)

Avanos Medical's Total Non-Current Liabilities history spans 10 years, with the latest figure at $425.3 million for Q2 2024.

  • For Q2 2024, Total Non-Current Liabilities changed N/A year-over-year to $425.3 million; the TTM value through Jun 2024 reached $425.3 million, changed N/A, while the annual FY2023 figure was $446.1 million, 6.12% down from the prior year.
  • Total Non-Current Liabilities for Q2 2024 was $425.3 million at Avanos Medical, down from $1.7 billion in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $1.7 billion in Q1 2024 and bottomed at $323.9 million in Q4 2021.
  • The 5-year median for Total Non-Current Liabilities is $435.7 million (2023), against an average of $625.0 million.
  • The largest annual shift saw Total Non-Current Liabilities fell 23.6% in 2020 before it soared 46.71% in 2022.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $399.7 million in 2020, then fell by 18.96% to $323.9 million in 2021, then skyrocketed by 46.71% to $475.2 million in 2022, then dropped by 6.12% to $446.1 million in 2023, then dropped by 4.66% to $425.3 million in 2024.
  • Per Business Quant, the three most recent readings for AVNS's Total Non-Current Liabilities are $425.3 million (Q2 2024), $1.7 billion (Q1 2024), and $446.1 million (Q4 2023).